Pay in 4 interest-free payments of $7.04 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
NIDDK Emerging Therapies and Oral GLP-1 Options Eli Lillys development of orforglipron, an oral GLP-1 receptor agonist, marks a significant advancement in diabetes treatment
10.3390/biom12081035 Summary Keywords alcohol-related liver disease, cell death patterns, intestinal flora, immune response, molecular mechanisms, therapeutic strategy, animal models Citation Hong X, Huang S, Jiang H, Ma Q, Qiu J, Luo Q, Cao C, Xu Y, Chen F, Chen Y, Sun C, Fu H, Liu Y, Li C, Chen F and Qiu P (2024) Alcohol-related liver disease (ALD): current perspectives on pathogenesis, therapeutic strategies, and animal models
Induction of erythroid differentiation in human erythroleukemia cells by depletion of malic enzyme 2
Glucagon-like peptide-1 receptor agonists, aka GLP-1 drugs, were originally approved and used for treatment of Type 2 diabetes, with the first product debuting in 2005
2016;11(9):e0163037
US$ 25.98
US$ 22.52
US$ 27.21
US$ 29.35
